Published in Eur Psychiatry on August 01, 2005
Subjective and objective quality of life in schizophrenia. Schizophr Res (2007) 1.21
Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother (2010) 1.15
Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigation. Schizophr Bull (2010) 1.04
Very poor outcome schizophrenia: clinical and neuroimaging aspects. Int Rev Psychiatry (2007) 1.04
Disorganization and reality distortion in schizophrenia: a meta-analysis of the relationship between positive symptoms and neurocognitive deficits. Schizophr Res (2010) 1.02
Neurocognitive deficits and prefrontal cortical atrophy in patients with schizophrenia. Schizophr Res (2007) 0.90
Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum. Neuropsychopharmacology (2010) 0.89
The importance of measuring psychosocial functioning in schizophrenia. Ann Gen Psychiatry (2011) 0.89
Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis. Schizophr Bull (2009) 0.88
Prediction of community outcome in schizophrenia 1 year after discharge from inpatient treatment. Eur Arch Psychiatry Clin Neurosci (2007) 0.87
Developmental Inhibition of Gsk3 Rescues Behavioral and Neurophysiological Deficits in a Mouse Model of Schizophrenia Predisposition. Neuron (2016) 0.86
Neurocognition, insight into illness and subjective quality-of-life in schizophrenia: what is their relationship? Schizophr Res (2011) 0.83
Reduction in perseverative errors with adjunctive ethyl-eicosapentaenoic acid in patients with schizophrenia: Preliminary study. Prostaglandins Leukot Essent Fatty Acids (2011) 0.78
Sustained attention in psychosis: Neuroimaging findings. World J Radiol (2014) 0.77
The Relationship between Attention/Vigilance and Symptom Severity in Schizophrenic Patients. Iran J Psychiatry (2012) 0.77
Subjective and Objective Cognitive Dysfunction in Schizophrenia - is there a Link? Front Psychol (2011) 0.77
Cognitive and oculomotor performance in subjects with low and high schizotypy: implications for translational drug development studies. Transl Psychiatry (2016) 0.75
QLiS-SF: Development of a short form of the quality of life in schizophrenia questionnaire. BMC Psychiatry (2017) 0.75
Better mental component of quality of life in amputee. Iran J Public Health (2012) 0.75
Transdiagnostic neural markers of emotion-cognition interaction in psychotic disorders. J Abnorm Psychol (2016) 0.75
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet (2008) 6.24
Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry (2005) 2.58
Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication. Pharmacopsychiatry (2004) 1.82
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry (2009) 1.71
Incomplete improvement of visuo-motor deficits in patients with minimal hepatic encephalopathy after liver transplantation. Liver Transpl (2004) 1.70
Osteoporosis in patients with schizophrenia. Am J Psychiatry (2005) 1.58
A randomized trial of short psychotherapy versus sustained-release bupropion for smoking cessation. Addiction (2008) 1.49
Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenia patient. J Clin Psychiatry (2003) 1.46
Attitudes towards medication in patients with schizophrenia. Acta Psychiatr Scand (2006) 1.44
Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging (2009) 1.40
Reversal of cocaine-conditioned place preference and mesocorticolimbic Zif268 expression by social interaction in rats. Addict Biol (2011) 1.36
Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol Aging (2006) 1.33
The duration of the suicidal process: how much time is left for intervention between consideration and accomplishment of a suicide attempt? J Clin Psychiatry (2008) 1.32
Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication. J Clin Psychiatry (2004) 1.25
Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry (2012) 1.20
Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry (2012) 1.20
Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr. Eur J Haematol (2004) 1.18
Factors influencing compliance in schizophrenia patients. J Clin Psychiatry (2003) 1.16
Implementation of computer-based quality-of-life monitoring in brain tumor outpatients in routine clinical practice. J Pain Symptom Manage (2010) 1.15
Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord (2005) 1.15
Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs). Breast Cancer Res Treat (2011) 1.13
Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry (2004) 1.13
Brain activation patterns during a selective attention test--a functional MRI study in healthy volunteers and unmedicated patients during an acute episode of schizophrenia. Psychiatry Res (2006) 1.11
Normative data for functional assessment of cancer therapy--general scale and its use for the interpretation of quality of life scores in cancer survivors. Acta Oncol (2004) 1.10
Gender differences in regional cerebral activity during the perception of emotion: a functional MRI study. Neuroimage (2006) 1.08
Olfactory functions and volumetric measures of orbitofrontal and limbic regions in schizophrenia. Schizophr Res (2005) 1.08
Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res (2005) 1.07
Cognitive remediation therapy during treatment for alcohol dependence. J Stud Alcohol Drugs (2012) 1.06
Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease. Am J Geriatr Psychiatry (2010) 1.04
Attitudes of patients with schizophrenia toward placebo-controlled clinical trials. J Clin Psychiatry (2003) 1.04
Various bilateral olfactory deficits in male patients with schizophrenia. Schizophr Bull (2005) 1.04
Facial emotion recognition and its relationship to symptomatic, subjective, and functional outcomes in outpatients with chronic schizophrenia. Eur Psychiatry (2008) 1.03
Taste alterations in cancer patients receiving chemotherapy: a neglected side effect? Oncologist (2010) 1.02
Fatigue in ovarian carcinoma patients: a neglected issue? Cancer (2003) 1.02
Never too old for eating disorders or body dissatisfaction: a community study of elderly women. Int J Eat Disord (2006) 1.01
Brain activation patterns during a selective attention test-a functional MRI study in healthy volunteers and patients with schizophrenia. Psychiatry Res (2003) 1.01
An FMRI study of episodic encoding and recognition of words in patients with schizophrenia in remission. Am J Psychiatry (2003) 1.01
Reduced olfactory sensitivity, discrimination, and identification in patients with alcohol dependence. Alcohol Clin Exp Res (2003) 1.01
Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res (2009) 1.00
Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials - a systematic review to evaluate the added value in supporting clinical decision making. Eur J Cancer (2008) 0.99
Measurement of tryptophan, kynurenine and neopterin in women with and without postpartum blues. J Affect Disord (2005) 0.98
Sublingual buprenorphine and methadone maintenance treatment: a three-year follow-up of quality of life assessment. ScientificWorldJournal (2005) 0.98
Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. Eur Arch Psychiatry Clin Neurosci (2005) 0.97
Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res (2013) 0.97
Quality of life in adult hematopoietic cell transplant patients at least 5 yr after treatment: a comparison with healthy controls. Eur J Haematol (2005) 0.97
Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it? Int J Neuropsychopharmacol (2012) 0.95
No evidence for an association between serum cholesterol and the course of depression and suicidality. Psychiatry Res (2004) 0.95
Quality of life trajectory in patients with advanced cancer during the last year of life. J Palliat Med (2011) 0.94
Language lateralization in unmedicated patients during an acute episode of schizophrenia: a functional MRI study. Psychiatry Res (2006) 0.94
Low bone mineral density and impaired bone metabolism in young alcoholic patients without liver cirrhosis: a cross-sectional study. Alcohol Clin Exp Res (2008) 0.94
Sex differences in brain activation patterns during processing of positively and negatively valenced emotional words. Psychol Med (2006) 0.93
The EORTC emotional functioning computerized adaptive test: phases I-III of a cross-cultural item bank development. Psychooncology (2013) 0.92
Impairment in emotion recognition abilities in patients with mild cognitive impairment, early and moderate Alzheimer disease compared with healthy comparison subjects. Am J Geriatr Psychiatry (2008) 0.92
Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry (2003) 0.92
Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective. CNS Drugs (2013) 0.92
Cross-cultural development of an item list for computer-adaptive testing of fatigue in oncological patients. Health Qual Life Outcomes (2011) 0.91
Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry (2002) 0.91
Influence of age and gender on risperidone plasma concentrations. J Psychopharmacol (2005) 0.91
Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period. Schizophr Res (2005) 0.91
Longitudinal volumetric MRI study in first- and multiple-episode male schizophrenia patients. Psychiatry Res (2005) 0.91
Do neurooncological patients and their significant others agree on quality of life ratings? Health Qual Life Outcomes (2009) 0.91
Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol (2010) 0.90
Placebo or active control trials of antipsychotic drugs? Arch Gen Psychiatry (2003) 0.90
Brain activation patterns during a verbal fluency test-a functional MRI study in healthy volunteers and patients with schizophrenia. Schizophr Res (2004) 0.90
The clinical relevance of percentage improvements on the PANSS score. Neuropsychopharmacology (2007) 0.89